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Genomic medicine, in its broadest sense of being medical 
developments informed by ‘omic’ advances, has con­
tinued to move towards the clinic in 2011. To mark the 
end of the year and the beginning of 2012, the editors of 
the six sections within Genome Medicine were invited to 
provide their highlights of the past year and to hint at the 
developments that we are likely to see in the near future.
Six different areas of progress are covered here, but the 
core of genomic medicine continues to be intrinsically 
linked to improvements in the underlying technology, 
and two obvious examples are sequencing and mass 
spec trometry. Technological advances have enabled 
larger studies and more complex analyses, allowing 
researchers and clinicians to track changes within a single 
cell and yet spot patterns across a whole population and 
within an entire physiological system. The foundations 
laid in 2011 should help the field to tackle the challenges 
of translating genomic medicine to the clinic in 2012.
Complex genomic rearrangements and disease
The past year has been marked by advances in the speed, 
accuracy and scale of genome sequencing. These improve­
ments have led to the first population­scale genome 
sequencing study to provide information on structural 
variants [1]. Over 15,000 novel structural variants were 
identified from 185 individuals. Analysis of breakpoint 
junctions revealed that 70% of deletions and almost 90% 
of insertions showed microhomology ranging from 2 bp 
to 376 bp at the junctions. This suggests that nonhomolo­
gous recombination mechanisms are predominant in 
copy number variation, and that microhomology­mediated 
DNA replication mechanisms, such as microhomology­
mediated break­induced replication, might have a major 
role in human genome structural variation.
Genome sequencing also revealed the extent of 
complex genomic rearrangements (CGRs) in disease. 
Over 700 genomes from different cancers were studied, 
and ‘chromosome catastrophes’ were identified in 2 to 3% 
of all cancers and in up to 25% of bone cancers [2]. This 
phenomenon, also termed ‘chromothripsis’ (shattering 
and regluing of chromosomes), is primarily localized to 
single chromosomes, but includes multiple structural 
genomic changes, such as gains, losses and inversions. As 
a result, chromothripsis can lead to the simultaneous 
occurrence of mutations in a number of different cancer­
causing genes. Cancer is known to be driven by somati­
cally acquired point mutations and chromosomal re­
arrangements, conventionally thought to accumulate 
gradually over time. However, chromothripsis is a one­off 
event resulting in multigenic changes [2]. It remains to be 
shown whether chromothripsis is a major driver of 
cancer.
Intriguingly, a similar chromosome catastrophe event 
that resulted in CGRs was found to be associated with a 
small fraction of genomic disorders [3]. This involved a 
germline or constitutional rearrangement event early in 
embryogenesis rather than somatically acquired muta­
tions and seemed to occur via a DNA­replication­based 
mechanism. Triplicated genomic segments were also 
identified within the rearrangements, and micro homology 
was present at many of the breakpoint junctions. The 
triplication cannot readily be explained by chromo thrip­
sis, as it requires a gain of genetic information, probably 
resulting from DNA replication. Other CGRs identified 
in association with genomic disorders included tripli­
cations; triplicated dosage­sensitive genes conveyed a 
more severe clinical phenotype than duplication. Tripli­
ca tions seem to occur by a double crossover event within 
a flanking low­copy repeat and are tandem in nature, 
similar to earlier predictions from an unequal crossing­
over or non­allelic homologous recombination (NAHR) 
model [4]. However, many of the observed triplications 
have a complex ‘duplication­inverted triplication­duplica­
tion’ structure, which requires only two breakpoint 
junctions. One of these is generated by an initial NAHR 
event between inverted repeats, and the other occurs by a 
nonhomologous mechanism, potentially a DNA replication­
based mechanism that results in microhomology at the 
breakpoint junction [5]. The inversion allows distant 
genomic regions to be brought into spatial proximity.
A summary of 2011 would not be complete without 
highlighting exome sequencing and its role in the 
elucidation of the gene(s) responsible for a number of © 2010 BioMed Central Ltd
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different Mendelian disorders [6]. Genomic studies have 
so far revealed the tremendous extent of rare variants in 
individual genomes. This has led to the concept of ‘clan 
genomics’ [7], wherein the most relevant medically 
actionable variation may be rare variants that occurred as 
novel combinations or as new mutations in your personal 
genome or that of your nearest relatives.
James R Lupski, Section Editor, 
Molecular genetics, genomics & epigenetics of disease
Bringing quantification to the proteome
The ability to conduct global analysis of proteomes has 
existed for about a decade now. During this period most 
of the progress has been on increasing the number of 
proteins identified within the proteome. Because of the 
lack of inherent quantification within the data supplied 
by high­throughput mass spectrometry (MS), measuring 
the absolute concentration of proteins across the pro­
teome has lagged behind. This situation is analogous to 
having a recipe in which the ingredients are listed but the 
amount of each required is not supplied. Without know­
ing how much of each ingredient to add, it is unlikely that 
the dish would taste very good.
Recent studies have moved to develop techniques to 
supply this vital piece of information. Selbach and colleagues 
[8] used a combination of stable isotope incorporation 
and MS to quantify pulse­labeled proteins and 4­thiouridine 
incorporation to quantify newly synthesized RNA in 
mouse cells. These results showed that genes that 
respond quickly to stimuli (such as those encoding trans­
cription factors and signaling proteins) have short protein 
and mRNA half lives. Constitutive processes (such as 
translation and central metabolism) were populated by 
genes giving rise to stable proteins and mRNA. A more 
recent study by Aebersold and colleagues [9] provided an 
absolute quantitative estimate of approximately 7,000 
proteins in a human cell line during exponential and M­
phase growth. This study also found that proteins related 
to translation were found in high abundance, whereas 
those involved in processes such as transcription and 
signaling are present in very low abundance. These 
results are in agreement with those found by Selbach and 
colleagues [8], with both studies suggesting that the 
correlation between mRNA and protein levels is greater 
than previously reported [10,11].
Although it is possible to measure the absolute number 
of specific proteins within complex mixtures [12], these 
studies represent a new, hopefully broader, effort in 
determining the absolute abundances of proteins across 
an entire proteome. Frankly, without this quantitative 
information it is impossible to accurately understand 
cellular processes at a systems­level view.
Timothy Veenstra, Section Editor, 
Post-genomic advances in medicine
The human microbiome, our personal health and 
diseases
Microbial cells in the human body outnumber human 
cells by two orders of magnitude. During the past decade, 
there has been growing interest in the analysis of these 
microbial communities, which are an integral part of the 
human body and provide us with nutrients essential to 
our health. With the rapid increase in sequencing power, 
the characterization of the so­called ‘microbiome’ has 
given rise to large ‘metagenomic’ datasets, revealing a 
wealth of microbial species that were previously un­
known and cannot be cultured.
The gut microbiome is the most extensively studied 
part of the human microbiome so far, and this past year 
the international MetaHIT Consortium has consolidated 
the data to support the existence of a limited number of 
‘enterotypes’, stable clusters of bacterial communities that 
are common to groups of individuals belonging to differ­
ent human populations rather than specific for each 
popu lation [13,14]. Enterotypes are ‘well­balanced host­
microbial symbiotic states that might respond differently 
to diet and drug intake’ and warrant functional analysis 
to complement species identification obtained through 
next­generation sequencing.
The same sequencing approach is being successfully 
extended to characterize the microbiome in other human 
tissues, such as nasal passages, oral cavities, skin and 
urogenital tract within the Human Microbiome Project 
[15,16]. Significant challenges remain in establishing 
robust and efficient bioinformatics pipelines to deal with 
the very large sequence datasets generated [17], but the 
integration of metagenomics with functional genomics 
has started to provide new insights into the role of the 
microbiome in health and in disease susceptibility, diag­
nosis, progression and treatment, as reviewed extensively 
by Nicholson and colleagues in this journal [18]. Although 
emphasis so far has been on bacterial communities, 
metagenomics provide simultaneous access to fungi, 
protozoa and viruses, revealing that the vast majority had 
not been identified through classical culture­based 
techniques. Functional metagenomics is thus opening a 
window into an as­yet largely unexplored biological 
world, and is starting to fill gaps in our knowledge of 
health and diseases. It is likely that microbiome studies 
will flourish in the coming years and will contribute to a 
more personal appraisal of our medical condition and 
potential response to treatment.
Charles Auffray, Section Editor, 
Systems medicine and informatics
Progress in pharmacogenomics and individualized 
medicine
In the past year some very important contributions have 
been made indicating that genomic information predicts 
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drug response and adverse drug reactions, thereby 
promoting the concept of personalized medicine and 
pharmacogenomics. Although the integration of individ­
ual ized medicine into clinical decision making is still 
limited [19], there is increasing evidence for genetic 
markers for major drug­induced hypersensitivity reac­
tions in the major histocompatibility complex (MHC) 
region. Examples of such adverse reactions include the 
Steven­Johnson syndrome (SJS) and the related toxic 
epidermal necrolysis (TEN), with mortalities of 10% and 
30%, respectively.
Carbamazepine, an antiepileptic drug also used for 
treatment of other conditions, including bipolar dis­
orders, and for pain management in trigeminal 
neuralgia, induces different manifestations of these 
hypersensitivity reactions. In 2004 the HLA­B*1502 
allele was strongly associated with SJS/TEN in Han 
Chinese people [20]. In a recent study, 4,855 Taiwanese 
were prospectively screened for the HLA­B*1502 allele 
before onset of carbamazepine treatment, and all HLA­
B*1502­positive people (7.7%) were offered alternative 
medications to carba mazepine and did not develop SJS/
TEN [21]. Although the estimated historical incidence 
for SJS/TEN in Southeast Asians is 0.23%, no cases of 
SJS/TEN were identified among the 4,120 study 
participants treated with carbamazepine. This prospec­
tive study clearly indicates that genetic testing for HLA­
B*1502 seems to be warranted in clinical practice for 
the prevention of carbamazepine­associated SJS/TEN in 
Southeast Asians.
Recent data have suggested that different HLA alleles 
might contribute to carbamazepine­related hypersensi­
tivity reactions in patients with other ethnic backgrounds 
[22], and a genome­wide association study (GWAS) 
found a strong association for the HLA­A*3101 allele in 
22 people with Northern European ancestry and carba­
mazepine­induced hypersensitivity reactions, as compared 
with 2,691 healthy controls [23]. Whereas the HLA­
B*1502 allele seems to be a phenotype­specific predictor 
for the development of SJS/TEN in Asians, in Europeans 
the HLA­A*3101 allele seems to be associated with 
multiple phenotypes of carbamazepine hypersensitivity 
reactions, including SJS/TEN. In a separate GWAS, 
multiple HLA class I and II alleles were identified as 
susceptibility factors for idiosyncratic amoxicillin­
clavulanate­induced liver injury, further supporting the 
importance of genetic variation in the MHC region in 
idiosyncratic adverse drug reactions [24].
In addition to the major efforts to individualize drug 
therapy using genomic information alone, metabolomics 
promises significant achievements towards a better 
under standing of the potential relevance of genetic 
variants in disease susceptibility as well as drug therapy, 
by the study of metabolism at the global level. A highlight 
in this field was the first analysis that comprehensively 
combined genomic information (from GWAS) with non­
targeted metabolic profiling of serum from subjects of 
two independent cohorts (n = 2,820) for hypothesis 
genera tion [25]. Meta­analysis revealed 37 independent 
loci with genome­wide significance, providing not only 
new functional insights for disease susceptibility but also 
novel biochemical data for genotype­dependent reactions 
to drug therapy. This approach highlights the enormous 
potential of integrated analyses for pharmacology and 
clinical pharmacology in the near future.
Matthias Schwab, Section Editor, 
Personalized medicine & therapeutics
Beyond base pairs to bedside
In February 2011, more than 10 years after a draft 
sequence of the human genome was published, the US 
National Human Genome Research Institute announced 
its new strategic plan for genomic medicine from base 
pairs to bedside [26]. The plan calls for evaluating the 
structure and biology of genomes; understanding the 
biology of disease; advancing the science of medicine; 
and improving the effectiveness of healthcare. Never­
theless, fulfilling the promise of genomics in improving 
health requires a multidisciplinary research agenda 
beyond bench to bedside, an agenda that will demon­
strate added value of genome­based information for 
improving health in populations [27].
Currently, this translational research agenda is much 
less robust than discovery research, accounting for less 
than 2% of funded genomics research and research publi­
cations [28], but this is likely to change in the next decade 
as more and more applications make it to the bedside. 
Ongoing horizon scanning for genomic tests has revealed 
more than 330 genomic tests have reached the bedside 
since 2009 [29]. In addition, the US Food and Drug 
Administration has provided drug labeling information 
about adverse reactions for more than 80 gene­drug pairs 
[30].
With rapid improvements in technologies, we are 
seeing the leading edge of the applications of whole 
genome sequencing (WGS) in practice primarily in the 
identification of rare heritable conditions [31]. Deploying 
WGS in practice will require a systematic evidence­based 
approach to binning genes and gene variants into tiers 
based on levels of evidence for improving health; recently, 
Berg et al. [32] proposed a three­tier binning schema for 
WGS, based on the availability of information on their 
clinical validity and utility. The ultimate success of 
genomics for improving health will require adoption of 
evidence­based approaches for their use in clinical and 
public health practice.
Muin Khoury, Section Editor, 
Genomic epidemiology & public health genomics
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Direct-to-consumer testing
As genomic technologies advance at an accelerating pace, 
direct­to­consumer (DTC) genetic testing has emerged 
as a dominant area of ELSI (ethical, legal and social 
issues) inquiry. Indeed, over the past few years, DTC 
testing has received a tremendous amount of attention 
from policymakers, ELSI scholars and the popular press 
[33]. Although it remains uncertain whether this 
industry, which is fueled by the availability of cheap and 
efficient testing technologies, will attract a broad 
consumer base [34], its growth has triggered a diverse 
array of regulatory responses, from outright bans [35] to 
recommendations that call for the provision of accurate 
information and valid results [36].
The DTC industry has also allowed ELSI researchers to 
explore popular culture representations of genetics [37], 
how individuals react to genetic risk information and the 
motivations behind the use of DTC services [38]. Much 
of this research has provided surprising results ­ 
highlighting both problems (for example, the degree to 
which the benefits and limitations of testing are often 
misrepresented [39] and the reality that much provided 
risk information may be inaccurate [40]) and the fact that 
some concerns may not be as problematic as previously 
thought (for example, the degree to which people become 
anxious after receiving predisposition information [41]). 
Given the appearance of the DTC industry, ELSI 
researchers are now contemplating future policy chal­
lenges. For example, the use of DTC services for the 
testing of children and the availability of cheap WGS, 
which is inevitable in the near future, seem likely to add 
new and challenging dimensions to the DTC story.
Timothy Caulfield, Section Editor, 
Social, ethical & legal issues in genomic medicine
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